Systemic and topical antiviral treatment for CMV anterior uveitis in patients
Official title: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO)
Funded at University of California, San Francisco · NIH-11517253 · Data updated 2026-11-12
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $16,460 |
| NIH project number | 3UG1EY036344-01A1S3 |
| Project ID | NIH-11517253 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with CMV anterior uveitis who may be candidates for systemic antiviral therapy, topical antiviral drops, or observation.
✕Less likely to help
Patients with CMV anterior uveitis for whom standard care is already clearly effective may not see new benefits.
What this research studies
This project focuses on CMV anterior uveitis, a condition causing eye inflammation that can lead to vision loss. It compares systemic antiviral therapy (like valganciclovir) with topical antiviral eye drops and other management approaches in people with this eye disease. The study aims to clarify which treatment approach gives better outcomes and fewer side effects, using real patient data and clinical observations from the UCSF setting. By improving understanding of how to treat CMV eye infections, the research hopes to reduce complications such as glaucoma and corneal damage.
Why it matters
Potential benefit: If successful, patients could receive clearer guidance on the most effective and safer antiviral treatment for CMV anterior uveitis, potentially preserving vision.
How similar studies have gone: Previous work suggests variable responses to antiviral therapies, but randomized comparisons in this area are limited.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gonzales, John Alexander — University of California, San Francisco
- Study coordinator: Gonzales, John Alexander
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.